About Spexis AG

Company Description

Headquartered in Switzerland and Boston, two global biotech-hubs, our ambition is to develop Spexis into a leading biopharmaceutical company with a strategic focus on rare diseases, oncology and antimicrobial resistance. With a strong scientific core, our drug discovery and research efforts are led by our in house scientist via leveraging our discovery platforms in collaboration with top academic centers around the globe. We have two clinical programs focused on products for rare, chronic respiratory diseases.

Spexis AG is a combination of the two legacy companies, Polyphor, a publicly listed Swiss biotech and EnBiotix, a privately held US biotech. In December 2021, two companies – Polyphor and EnBiotix – teamed up to join forces and formed Spexis.

Year founded

1996

Served area

Worldwide

Headcount

28

Headquarters

Hegenheimermattweg 125, 4123 Allschwil – Switzerland

Shareholder information

Shares outstanding

47,712,037

IPO

May 15, 2018

Stock exchange(s)

SIX Swiss Exchange

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.